SUNPHARMA's weekly performance was disappointing, with a -1.0% return, underperforming its peers. The stock's high volatility of 32.46% contributed to its poor performance, making it a risky investment this week. Compared to its peers, SUNPHARMA's return was lower than HINDUNILVR and DIVISLAB, but better than DRREDDY. Overall, the stock's Sharpe Ratio of -0.12 and Max Drawdown of -3.59% suggest that its returns were not justified by its level of risk.

[Volatility: 32.46%]